ES2637072T3 - Formulación parenteral de antibióticos macrólidos - Google Patents

Formulación parenteral de antibióticos macrólidos Download PDF

Info

Publication number
ES2637072T3
ES2637072T3 ES11754115.1T ES11754115T ES2637072T3 ES 2637072 T3 ES2637072 T3 ES 2637072T3 ES 11754115 T ES11754115 T ES 11754115T ES 2637072 T3 ES2637072 T3 ES 2637072T3
Authority
ES
Spain
Prior art keywords
composition
cem
pharmaceutical composition
agent
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11754115.1T
Other languages
English (en)
Spanish (es)
Inventor
David E. Pereira
Prabhavathi Fernandes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cempra Pharmaceuticals Inc
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2637072T3 publication Critical patent/ES2637072T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES11754115.1T 2010-03-10 2011-03-10 Formulación parenteral de antibióticos macrólidos Active ES2637072T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31241710P 2010-03-10 2010-03-10
US312417P 2010-03-10
PCT/US2011/027984 WO2011112864A1 (en) 2010-03-10 2011-03-10 Parenteral formulations of macrolide antibiotics

Publications (1)

Publication Number Publication Date
ES2637072T3 true ES2637072T3 (es) 2017-10-10

Family

ID=44563855

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11754115.1T Active ES2637072T3 (es) 2010-03-10 2011-03-10 Formulación parenteral de antibióticos macrólidos

Country Status (11)

Country Link
US (3) US20130045937A1 (enExample)
EP (1) EP2544537B1 (enExample)
JP (1) JP5890785B2 (enExample)
CN (2) CN109091489A (enExample)
AU (1) AU2011224238B2 (enExample)
CA (1) CA2792616A1 (enExample)
DK (1) DK2544537T3 (enExample)
ES (1) ES2637072T3 (enExample)
PL (1) PL2544537T3 (enExample)
SI (1) SI2544537T1 (enExample)
WO (1) WO2011112864A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601695B2 (en) 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
CN102245195B (zh) 2008-10-24 2016-01-13 森普拉制药公司 使用含三唑的大环内酯的生物防御
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
JP5914335B2 (ja) * 2009-09-10 2016-05-11 センプラ ファーマシューティカルズ，インコーポレイテッド マラリア、結核、及びｍａｃ病の治療方法
EP3009442B1 (en) 2010-03-22 2019-06-19 Cempra Pharmaceuticals, Inc. Crystalline forms of a macrolide, and uses therefor
CA2799937A1 (en) 2010-05-20 2011-11-24 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
WO2012034058A1 (en) 2010-09-10 2012-03-15 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CA2868262A1 (en) * 2012-03-27 2013-10-03 Cempra Pharmaceuticals, Inc. Parenteral formulations for administering macrolide antibiotics
HK1217665A1 (zh) 2013-03-14 2017-01-20 森普拉制药公司 用於治療呼吸道疾病的方法及其製劑
HK1218864A1 (zh) 2013-03-15 2017-03-17 森普拉制药公司 用於制备大环内酯抗菌剂的收敛方法
KR102363621B1 (ko) 2013-04-04 2022-02-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 매크롤라이드 그리고 그의 제조방법 및 용도
RU2015154737A (ru) 2013-05-22 2017-06-27 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
JP2017523975A (ja) * 2014-08-05 2017-08-24 センプラ ファーマシューティカルズ，インコーポレイテッド 経口抗菌薬粉末懸濁製剤
CA2963815A1 (en) 2014-10-08 2016-04-14 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
WO2016154591A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
CA3144443A1 (en) * 2019-06-28 2020-12-30 Moleculin Biotech, Inc. Method of reconstituting liposomal annamycin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20040019012A1 (en) * 2002-02-22 2004-01-29 Singh Satish K. Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
US7601695B2 (en) * 2003-03-10 2009-10-13 Optimer Pharmaceuticals, Inc. Antibacterial agents
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
CN101045063B (zh) * 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方

Also Published As

Publication number Publication date
CN109091489A (zh) 2018-12-28
EP2544537A1 (en) 2013-01-16
US20130045937A1 (en) 2013-02-21
JP5890785B2 (ja) 2016-03-22
US20200276150A1 (en) 2020-09-03
JP2013522229A (ja) 2013-06-13
SI2544537T1 (sl) 2017-12-29
EP2544537A4 (en) 2014-05-14
DK2544537T3 (en) 2017-08-28
AU2011224238B2 (en) 2015-11-26
AU2011224238A1 (en) 2012-10-04
EP2544537B1 (en) 2017-05-10
WO2011112864A1 (en) 2011-09-15
CN102811616A (zh) 2012-12-05
PL2544537T3 (pl) 2017-10-31
CA2792616A1 (en) 2011-09-15
US20190054059A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
ES2637072T3 (es) Formulación parenteral de antibióticos macrólidos
US10188674B2 (en) Parenteral formulations for administering macrolide antibiotics
ES2384451T3 (es) Aplicación de levo-ornidazol en la preparación de un medicamento contra la infección de bacterias anaeróbicas .
ES2356242T3 (es) Preparación liofilizada conteniendo metilcobalamina y procedimiento de producción de esta preparación.
ES3041708T3 (en) Liquid pharmaceutical composition demonstrating excellent preservation efficacy
EA022765B1 (ru) Фармацевтическая композиция
EP2303228B1 (en) Fosphenytoin composition
ES2862209T3 (es) Composiciones orales sólidas de liberación prolongada no pulsátil que contienen betahistina
HK40002820A (en) Parenteral formulations of macrolide antibiotics
HK1179115A (en) Parenteral formulations of macrolide antibiotics
ES2346573T3 (es) Composiciones de cefquinoma y metodos para su uso.
HK1180184B (en) Parenteral formulations of macrolide antibiotics
HK1180184A (en) Parenteral formulations of macrolide antibiotics
KR20160090312A (ko) 조산 조건의 치료에서 사용을 위한 용량 단위의 조합
CA3091413A1 (en) Triazole-containing macrolides and ophthalmic uses therefor
HK1208622B (zh) 用於施用大环内酯抗生素的肠胃外制剂